Advertisement
Advertisement
RNXT
RenovoRx, Inc. Common Stock
1.49
USDSponsored
+0.06
+4.56%
Oct 29, 15:59 UTC -4
Closed
After-Market
1.50
+0.01
+0.60%
RenovoRx, Inc. Common Stock (RNXT) Earnings
RNXT Earnings Reports
Positive Surprise Ratio
RNXT beat 13 of 20 last estimates.
65%
Next Report
Next Week
Date of Next Report
Nov 05, 2026
Estimate for Q3 26 (Revenue/ EPS)
$1.09M
/-$0.06
Implied change from Q2 26 (Revenue/ EPS)
+19.45%
/+20.00%
Implied change from Q3 25 (Revenue/ EPS)
+308.19%
/-25.00%
RenovoRx, Inc. Common Stock earnings per share and revenue
On Aug 12, 2026, RNXT reported earnings of -0.05 USD per share (EPS) for Q2 26, beating the estimate of -0.07 USD, resulting in a 32.43% surprise. Revenue reached 909.00 thousand, compared to an expected 730.83 thousand, with a 24.38% difference. The market reacted with a +12.50% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 5 analysts forecast an EPS of -0.06 USD, with revenue projected to reach 1.09 million USD, implying an increase of 20.00% EPS, and increase of 19.45% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
NovoCure Limited Ordinary Shares
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.09
Surprise
+63.88%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.14
Actual
$0.04
Surprise
+128.27%
Gilead Sciences Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$2.24
Actual
$2.54
Surprise
+13.66%
Bristol-Myers Squibb Co.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.20
Actual
$1.35
Surprise
+11.66%
Illumina Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.38
Actual
$1.44
Surprise
+4.18%
Alnylam Pharmaceuticals, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.65
Actual
$16.26
Surprise
+885.34%
Incyte Genomics Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$3.92
Actual
-$3.60
Surprise
+8.33%
Exelixis Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.81
Actual
$0.94
Surprise
+15.64%
Kymera Therapeutics, Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$1.29
Actual
-$1.32
Surprise
-2.17%
Ligand Pharmaceuticals Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$2.42
Actual
$2.67
Surprise
+9.91%
FAQ
What were RenovoRx, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, RenovoRx, Inc. Common Stock reported EPS of -$0.05, beating estimates by 32.43%, and revenue of $909.00K, 24.38% above expectations.
How did the market react to RenovoRx, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 12.5%, changed from $1.12 before the earnings release to $1.26 the day after.
When is RenovoRx, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 05, 2026.
What are the forecasts for RenovoRx, Inc. Common Stock's next earnings report?
Based on 5
analysts, RenovoRx, Inc. Common Stock is expected to report EPS of -$0.06 and revenue of $1.09M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.